Wiktoria Napiórkowska
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Wiktoria Napiórkowska has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Agata Kotłowska
Nicolaus Copernicus Hospital, Copernicus PL Sp. z o.o., Gdańsk, Poland
8 shared publications - Aleksandra Izabela Masłowska
Military Institute of Medicine – National Research Institute, Szaserów 128, 04-141 Warsaw, Poland
8 shared publications - Anna Gwóźdź-Broczkowska
Military Institute of Medicine – National Research Institute, Szaserów 128, 04-141 Warsaw, Poland
8 shared publications - Julia Lenkiewicz
Nicolaus Copernicus Hospital, Copernicus PL Sp. z o.o., Gdańsk, Poland
8 shared publications - Marcin Trzciński
Nicolaus Copernicus Hospital, Copernicus PL Sp. z o.o., Gdańsk, Poland
8 shared publications - Oliwia Lenkiewicz
Nicolaus Copernicus Hospital, Copernicus PL Sp. z o.o., Gdańsk, Poland
8 shared publications
Latest Publications
- Open Access
- 22 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 4 (3(51))
THE IMPACT OF POSTOPERATIVE COFFEE CONSUMPTION ON POSTOPERATIVE ILEUS: A NARRATIVE REVIEW
Postoperative ileus (POI) is a multifactorial condition causing the transient cessation of bowel motility, which significantly increases patient morbidity and healthcare costs. This narrative review synthesizes current clinical evidence evaluating the efficacy, safety, and underlying mechanisms of early postoperative coffee administration in mitigating POI. A structured literature search of PubMed/MEDLINE, Cochrane Central Register of Controlled Trials, and Scopus was conducted, focusing on randomized controlled trials, systematic reviews, and meta-analyses that assessed early coffee consumption against standard care in human surgical cohorts. Clinical data consistently demonstrate that coffee significantly accelerates gastrointestinal recovery across colorectal, gynecological, general abdominal, and obstetric surgeries. The intervention effectively reduces the time to first flatus, first defecation, and the tolerance of solid food. These prokinetic benefits are driven by cephalic-vagal reflex stimulation, gastrointestinal hormone secretion, and intrinsic anti-inflammatory properties, with decaffeinated formulations showing comparable efficacy to caffeinated ones. Furthermore, coffee demonstrates a favorable safety profile without elevating overall postoperative complication rates, including anastomotic leakage, and enhances patient compliance. Ultimately, postoperative coffee consumption is a universally accessible, safe, and low-cost dietary intervention that expedites bowel recovery and decreases hospital length of stay. Its routine integration into standardized Enhanced Recovery After Surgery pathways offers a highly pragmatic strategy for managing POI.
- 22 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 4 (3(51))
Open AccessTHE IMPACT OF POSTOPERATIVE COFFEE CONSUMPTION ON POSTOPERATIVE ILEUS: A NARRATIVE REVIEW
Postoperative ileus (POI) is a multifactorial condition causing the transient cessation of bowel motility, which significantly increases patient morbidity and healthcare costs. This narrative review synthesizes current clinical evidence evaluating the efficacy, safety, and underlying mechanisms of early postoperative coffee administration in mitigating POI. A structured literature search of PubMed/MEDLINE, Cochrane Central Register of Controlled Trials, and Scopus was conducted, focusing on randomized controlled trials, systematic reviews, and meta-analyses that assessed early coffee consumption against standard care in human surgical cohorts. Clinical data consistently demonstrate that coffee significantly accelerates gastrointestinal recovery across colorectal, gynecological, general abdominal, and obstetric surgeries. The intervention effectively reduces the time to first flatus, first defecation, and the tolerance of solid food. These prokinetic benefits are driven by cephalic-vagal reflex stimulation, gastrointestinal hormone secretion, and intrinsic anti-inflammatory properties, with decaffeinated formulations showing comparable efficacy to caffeinated ones. Furthermore, coffee demonstrates a favorable safety profile without elevating overall postoperative complication rates, including anastomotic leakage, and enhances patient compliance. Ultimately, postoperative coffee consumption is a universally accessible, safe, and low-cost dietary intervention that expedites bowel recovery and decreases hospital length of stay. Its routine integration into standardized Enhanced Recovery After Surgery pathways offers a highly pragmatic strategy for managing POI.
- Open Access
- 22 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 4 (3(51))
THE SIGNIFICANCE AND EFFICACY OF RESISTANCE EXERCISE IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA) – A CLINICAL AND MOLECULAR PERSPECTIVE
Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease characterized by progressive joint destruction and immunometabolic complications, notably rheumatoid cachexia. This review article investigates the significance and efficacy of resistance exercise in mitigating myopenia, sarcopenic obesity, and systemic inflammation in RA patients. The objective is to elucidate the underlying molecular mechanotransduction pathways, the role of myokines, and the clinical outcomes of progressive resistance training (PRT). A comprehensive review of the current literature, including recent randomized controlled trials and meta-analyses, was conducted to evaluate clinical and physiological effects. The findings indicate that PRT effectively counteracts muscle atrophy by activating the mTORC1 pathway and exerts potent anti-inflammatory effects via the release of muscle-derived interleukin-6 (IL-6). Furthermore, PRT demonstrates synergistic potential with modern biological and targeted synthetic disease-modifying anti-rheumatic drugs (DMARDs). Clinically, properly dosed PRT improves functional capacity, reduces cardiovascular risk, and alleviates patient-reported outcomes such as fatigue and sleep disruption, without exacerbating synovial inflammation or radiographic progression in stable RA. We conclude that structured resistance training is a crucial, evidence-based non-pharmacological therapy for RA — warranting equal consideration alongside standard aerobic exercises — and provide structured dosing guidelines based on the FITT-VP framework.
- 22 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 4 (3(51))
Open AccessTHE SIGNIFICANCE AND EFFICACY OF RESISTANCE EXERCISE IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA) – A CLINICAL AND MOLECULAR PERSPECTIVE
Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease characterized by progressive joint destruction and immunometabolic complications, notably rheumatoid cachexia. This review article investigates the significance and efficacy of resistance exercise in mitigating myopenia, sarcopenic obesity, and systemic inflammation in RA patients. The objective is to elucidate the underlying molecular mechanotransduction pathways, the role of myokines, and the clinical outcomes of progressive resistance training (PRT). A comprehensive review of the current literature, including recent randomized controlled trials and meta-analyses, was conducted to evaluate clinical and physiological effects. The findings indicate that PRT effectively counteracts muscle atrophy by activating the mTORC1 pathway and exerts potent anti-inflammatory effects via the release of muscle-derived interleukin-6 (IL-6). Furthermore, PRT demonstrates synergistic potential with modern biological and targeted synthetic disease-modifying anti-rheumatic drugs (DMARDs). Clinically, properly dosed PRT improves functional capacity, reduces cardiovascular risk, and alleviates patient-reported outcomes such as fatigue and sleep disruption, without exacerbating synovial inflammation or radiographic progression in stable RA. We conclude that structured resistance training is a crucial, evidence-based non-pharmacological therapy for RA — warranting equal consideration alongside standard aerobic exercises — and provide structured dosing guidelines based on the FITT-VP framework.
- Open Access
- 21 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 4 (3(51))
CONTEMPORARY IMAGING, ARTHROSCOPIC REPAIR, AND FUNCTIONAL REHABILITATION IN TRAUMATIC TRIANGULAR FIBROCARTILAGE COMPLEX TEARS: A NARRATIVE REVIEW
Traumatic triangular fibrocartilage complex (TFCC) tears are an important cause of ulnar-sided wrist pain, reduced grip strength, restricted forearm rotation, and distal radioulnar joint (DRUJ) instability. Their diagnosis and management remain challenging because morphological abnormalities do not always correlate with symptoms or functional impairment. This narrative review summarizes contemporary concepts in the diagnosis, treatment, and rehabilitation of traumatic TFCC tears, with particular emphasis on modern imaging and arthroscopic technologies. English-language publications were identified through PubMed without restrictions on publication year. The reviewed evidence indicates that diagnosis should integrate the mechanism of injury, physical examination, bilateral assessment of DRUJ stability, and imaging findings. Magnetic resonance imaging and magnetic resonance arthrography improve visualization of TFCC lesions, but incidental abnormalities and variable diagnostic performance limit their use as isolated decision-making tools. DRUJ stability appears to be a key factor in treatment selection. Structured non-operative management may provide satisfactory outcomes in patients with a stable DRUJ, whereas persistent symptoms, mechanically unstable tears, and foveal detachment may require surgical intervention. Contemporary arthroscopic options include all-inside repair, suture-anchor fixation, and transosseous techniques, although current evidence does not establish a single superior method. Postoperative rehabilitation protocols remain heterogeneous, and validated criteria for progression and return to work or sport are lacking. Future research should focus on standardized diagnostic pathways, comparative evaluation of repair techniques, objective functional monitoring, and patient-centered return-to-activity outcomes. Modern technologies should support, rather than replace, integrated clinical and functional assessment.
- 21 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 4 (3(51))
Open AccessCONTEMPORARY IMAGING, ARTHROSCOPIC REPAIR, AND FUNCTIONAL REHABILITATION IN TRAUMATIC TRIANGULAR FIBROCARTILAGE COMPLEX TEARS: A NARRATIVE REVIEW
Traumatic triangular fibrocartilage complex (TFCC) tears are an important cause of ulnar-sided wrist pain, reduced grip strength, restricted forearm rotation, and distal radioulnar joint (DRUJ) instability. Their diagnosis and management remain challenging because morphological abnormalities do not always correlate with symptoms or functional impairment. This narrative review summarizes contemporary concepts in the diagnosis, treatment, and rehabilitation of traumatic TFCC tears, with particular emphasis on modern imaging and arthroscopic technologies. English-language publications were identified through PubMed without restrictions on publication year. The reviewed evidence indicates that diagnosis should integrate the mechanism of injury, physical examination, bilateral assessment of DRUJ stability, and imaging findings. Magnetic resonance imaging and magnetic resonance arthrography improve visualization of TFCC lesions, but incidental abnormalities and variable diagnostic performance limit their use as isolated decision-making tools. DRUJ stability appears to be a key factor in treatment selection. Structured non-operative management may provide satisfactory outcomes in patients with a stable DRUJ, whereas persistent symptoms, mechanically unstable tears, and foveal detachment may require surgical intervention. Contemporary arthroscopic options include all-inside repair, suture-anchor fixation, and transosseous techniques, although current evidence does not establish a single superior method. Postoperative rehabilitation protocols remain heterogeneous, and validated criteria for progression and return to work or sport are lacking. Future research should focus on standardized diagnostic pathways, comparative evaluation of repair techniques, objective functional monitoring, and patient-centered return-to-activity outcomes. Modern technologies should support, rather than replace, integrated clinical and functional assessment.
- Open Access
- 7 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 3 (3(51))
DIETARY SUPPLEMENTS AND HERBAL PRODUCTS DURING ANTICANCER TREATMENT: PREVALENCE, INTERACTIONS AND THE PROBLEM OF NON-DISCLOSURE. A NARRATIVE REVIEW
Objectives: Dietary supplements and herbal products are widely used by patients undergoing anticancer treatment, and a considerable proportion of this use is never mentioned to their physician. This review summarises current evidence on the prevalence of such use, the pharmacological basis of interactions with anticancer agents, and the factors underlying non-disclosure on the part of both patients and clinicians. Methods: PubMed/MEDLINE and Google Scholar were searched for publications from January 2011, and July 2026, using combinations of terms relating to dietary supplements, herbal medicine, oncological treatment, herb–drug interactions and physician–patient communication. Priority was given to systematic reviews, meta-analyses and studies conducted in populations receiving anticancer treatment. Key findings: Reported prevalence varies widely between studies, depending on which products are counted and on the populations examined. Interactions arise principally through effects on drug metabolism and transport. Patients most often cite the absence of any question from the clinician as their reason for not disclosing; clinicians, in turn, describe their own knowledge of these products as insufficient. Training programmes have been developed to address this, but their effectiveness has yet to be established. Conclusions: Interactions between anticancer agents and dietary supplements or herbal products may be clinically relevant, yet often go unrecognised because their use is not disclosed. Non-disclosure is better understood as a feature of the consultation than as a behaviour of the patient. Two forms of intervention follow: strengthening clinicians' competence, and making enquiry about supplement use routine and free of judgement.
- 7 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 3 (3(51))
Open AccessDIETARY SUPPLEMENTS AND HERBAL PRODUCTS DURING ANTICANCER TREATMENT: PREVALENCE, INTERACTIONS AND THE PROBLEM OF NON-DISCLOSURE. A NARRATIVE REVIEW
Objectives: Dietary supplements and herbal products are widely used by patients undergoing anticancer treatment, and a considerable proportion of this use is never mentioned to their physician. This review summarises current evidence on the prevalence of such use, the pharmacological basis of interactions with anticancer agents, and the factors underlying non-disclosure on the part of both patients and clinicians. Methods: PubMed/MEDLINE and Google Scholar were searched for publications from January 2011, and July 2026, using combinations of terms relating to dietary supplements, herbal medicine, oncological treatment, herb–drug interactions and physician–patient communication. Priority was given to systematic reviews, meta-analyses and studies conducted in populations receiving anticancer treatment. Key findings: Reported prevalence varies widely between studies, depending on which products are counted and on the populations examined. Interactions arise principally through effects on drug metabolism and transport. Patients most often cite the absence of any question from the clinician as their reason for not disclosing; clinicians, in turn, describe their own knowledge of these products as insufficient. Training programmes have been developed to address this, but their effectiveness has yet to be established. Conclusions: Interactions between anticancer agents and dietary supplements or herbal products may be clinically relevant, yet often go unrecognised because their use is not disclosed. Non-disclosure is better understood as a feature of the consultation than as a behaviour of the patient. Two forms of intervention follow: strengthening clinicians' competence, and making enquiry about supplement use routine and free of judgement.
- Open Access
- 7 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 3 (3(51))
THE SIGNIFICANCE OF THE BCR::ABL1 BIOMARKER IN THE DIAGNOSIS AND TREATMENT MONITORING OF CHRONIC MYELOID LEUKEMIA: A NARRATIVE REVIEW
Chronic myeloid leukemia is defined by the presence of the BCR::ABL1 fusion, which plays a central role in disease pathogenesis, diagnosis, treatment selection, and molecular monitoring. This narrative review aimed to summarize the current clinical significance of BCR::ABL1, with particular emphasis on diagnostic methods, assessment of response to tyrosine kinase inhibitors, mechanisms of resistance, and treatment-free remission. A literature search was conducted using PubMed and Google Scholar, focusing primarily on English-language guidelines, review articles, and clinically relevant studies published between 2015 and 2025, while also including earlier landmark publications. The review shows that cytogenetic analysis, fluorescence in situ hybridization, and reverse-transcription polymerase chain reaction provide complementary diagnostic information. Serial RT-qPCR measurement of BCR::ABL1 on the International Scale remains the standard method for assessing the depth and kinetics of molecular response. Interpretation should consider previous results, treatment adherence, dose modifications, assay variability, and the overall clinical context. Detection of kinase-domain mutations, particularly T315I, may explain treatment resistance and guide subsequent TKI selection. Targeted next-generation sequencing and digital PCR may improve the detection of resistant subclones and low-level residual disease, but their findings should not be used as isolated treatment criteria. Overall, accurate and standardized BCR::ABL1 monitoring remains essential for individualized CML management, while further research is needed to validate additional prognostic markers and improve prediction of treatment-free remission.
- 7 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 3 (3(51))
Open AccessTHE SIGNIFICANCE OF THE BCR::ABL1 BIOMARKER IN THE DIAGNOSIS AND TREATMENT MONITORING OF CHRONIC MYELOID LEUKEMIA: A NARRATIVE REVIEW
Chronic myeloid leukemia is defined by the presence of the BCR::ABL1 fusion, which plays a central role in disease pathogenesis, diagnosis, treatment selection, and molecular monitoring. This narrative review aimed to summarize the current clinical significance of BCR::ABL1, with particular emphasis on diagnostic methods, assessment of response to tyrosine kinase inhibitors, mechanisms of resistance, and treatment-free remission. A literature search was conducted using PubMed and Google Scholar, focusing primarily on English-language guidelines, review articles, and clinically relevant studies published between 2015 and 2025, while also including earlier landmark publications. The review shows that cytogenetic analysis, fluorescence in situ hybridization, and reverse-transcription polymerase chain reaction provide complementary diagnostic information. Serial RT-qPCR measurement of BCR::ABL1 on the International Scale remains the standard method for assessing the depth and kinetics of molecular response. Interpretation should consider previous results, treatment adherence, dose modifications, assay variability, and the overall clinical context. Detection of kinase-domain mutations, particularly T315I, may explain treatment resistance and guide subsequent TKI selection. Targeted next-generation sequencing and digital PCR may improve the detection of resistant subclones and low-level residual disease, but their findings should not be used as isolated treatment criteria. Overall, accurate and standardized BCR::ABL1 monitoring remains essential for individualized CML management, while further research is needed to validate additional prognostic markers and improve prediction of treatment-free remission.
- Open Access
- 7 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 3 (3(51))
FROM A POSITIVE AUTOANTIBODY TO AUTOIMMUNE DISEASE: WHAT DOES THE EVIDENCE SHOW FOLLOWING VIRAL INFECTIONS?
Autoantibodies are commonly detected during or shortly after viral illness, sometimes in patients whose presentation already resembles a systemic or organ-specific autoimmune disorder. The difficulty is that the laboratory finding often arrives before the clinical meaning of that finding is clear. In acute parvovirus B19 and hepatitis E, ANA, RF or autoimmune liver serology may accompany the infection and then recede as the illness resolves. SARS-CoV-2 cohorts that include pre-infection samples show that genuine seroconversion can occur, but they also expose a separate problem: a newly detectable or persistent autoantibody is not the same endpoint as clinically defined autoimmune disease. HCV-associated cryoglobulinaemic vasculitis is different because infection, immune-complex formation and organ disease belong to the same pathogenic process. Across the other viral settings, interpretation is limited by referral bias, incomplete follow-up, assay heterogeneity and the frequent use of serological rather than clinical endpoints. Taken together, the recent literature supports post-viral autoreactivity far more consistently than it supports frequent progression to a new autoimmune disease. Diagnostic weight increases when the antibody is disease-concordant, persists beyond the acute infection and accompanies an objective phenotype that the infection no longer adequately explains.
- 7 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 3 (3(51))
Open AccessFROM A POSITIVE AUTOANTIBODY TO AUTOIMMUNE DISEASE: WHAT DOES THE EVIDENCE SHOW FOLLOWING VIRAL INFECTIONS?
Autoantibodies are commonly detected during or shortly after viral illness, sometimes in patients whose presentation already resembles a systemic or organ-specific autoimmune disorder. The difficulty is that the laboratory finding often arrives before the clinical meaning of that finding is clear. In acute parvovirus B19 and hepatitis E, ANA, RF or autoimmune liver serology may accompany the infection and then recede as the illness resolves. SARS-CoV-2 cohorts that include pre-infection samples show that genuine seroconversion can occur, but they also expose a separate problem: a newly detectable or persistent autoantibody is not the same endpoint as clinically defined autoimmune disease. HCV-associated cryoglobulinaemic vasculitis is different because infection, immune-complex formation and organ disease belong to the same pathogenic process. Across the other viral settings, interpretation is limited by referral bias, incomplete follow-up, assay heterogeneity and the frequent use of serological rather than clinical endpoints. Taken together, the recent literature supports post-viral autoreactivity far more consistently than it supports frequent progression to a new autoimmune disease. Diagnostic weight increases when the antibody is disease-concordant, persists beyond the acute infection and accompanies an objective phenotype that the infection no longer adequately explains.
- Open Access
- 27 August 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (3(51))
CURRENT ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPIES FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A NARRATIVE REVIEW OF AVAILABLE AGENTS AND TREATMENT STRATEGIES
Background: Neovascular age-related macular degeneration (nAMD) is a leading cause of irreversible central vision loss in older adults. Intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy has transformed disease management, but the expanding range of agents and evolving dosing strategies has complicated therapeutic decision-making. Objective: To summarize the anti-VEGF agents currently available for nAMD, compare their efficacy, safety and durability, and evaluate contemporary treatment strategies used to optimize long-term visual outcomes while minimizing treatment burden. Methods: A narrative literature review was conducted using PubMed and Google Scholar. Eligible publications included landmark randomized trials, real-world studies, systematic reviews, meta-analyses, consensus statements and international clinical guidelines addressing anti-VEGF pharmacotherapy and treatment regimens in nAMD, prioritizing high-quality evidence. Key Findings: Ranibizumab, aflibercept 2 mg, brolucizumab, faricimab, aflibercept 8 mg and the recently approved ophthalmic formulation bevacizumab-vikg all preserve or improve visual acuity. Functional outcomes are broadly comparable across agents, with meaningful differences confined to durability, anatomical fluid control and safety, most notably the intraocular inflammation signal associated with brolucizumab. Treat-and-extend dosing matched fixed dosing for visual acuity while requiring fewer injections and outperformed pro re nata regimens. Faricimab and aflibercept 8 mg maintained intervals of 12 weeks or longer in most patients, and switching agents improved anatomical outcomes in insufficiently responding eyes. Conclusions: Contemporary management of nAMD centers on individualized anti-VEGF therapy guided by disease activity, treatment response and patient-specific factors. Longer-acting agents and emerging approaches are expected to further improve disease control while reducing the burden of repeated intravitreal injections.
- 27 August 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (3(51))
Open AccessCURRENT ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPIES FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A NARRATIVE REVIEW OF AVAILABLE AGENTS AND TREATMENT STRATEGIES
Background: Neovascular age-related macular degeneration (nAMD) is a leading cause of irreversible central vision loss in older adults. Intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy has transformed disease management, but the expanding range of agents and evolving dosing strategies has complicated therapeutic decision-making. Objective: To summarize the anti-VEGF agents currently available for nAMD, compare their efficacy, safety and durability, and evaluate contemporary treatment strategies used to optimize long-term visual outcomes while minimizing treatment burden. Methods: A narrative literature review was conducted using PubMed and Google Scholar. Eligible publications included landmark randomized trials, real-world studies, systematic reviews, meta-analyses, consensus statements and international clinical guidelines addressing anti-VEGF pharmacotherapy and treatment regimens in nAMD, prioritizing high-quality evidence. Key Findings: Ranibizumab, aflibercept 2 mg, brolucizumab, faricimab, aflibercept 8 mg and the recently approved ophthalmic formulation bevacizumab-vikg all preserve or improve visual acuity. Functional outcomes are broadly comparable across agents, with meaningful differences confined to durability, anatomical fluid control and safety, most notably the intraocular inflammation signal associated with brolucizumab. Treat-and-extend dosing matched fixed dosing for visual acuity while requiring fewer injections and outperformed pro re nata regimens. Faricimab and aflibercept 8 mg maintained intervals of 12 weeks or longer in most patients, and switching agents improved anatomical outcomes in insufficiently responding eyes. Conclusions: Contemporary management of nAMD centers on individualized anti-VEGF therapy guided by disease activity, treatment response and patient-specific factors. Longer-acting agents and emerging approaches are expected to further improve disease control while reducing the burden of repeated intravitreal injections.
- Open Access
- 2 July 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (3(51))
PLASMA p-tau217 AS A MINIMALLY INVASIVE BIOMARKER FOR ALZHEIMER’S DISEASE DIAGNOSIS: ANALYTICAL PLATFORMS, DIAGNOSTIC PERFORMANCE, AND CLINICAL IMPLEMENTATION CHALLENGES
Background: Plasma phosphorylated tau at threonine 217 (p-tau217) has emerged as a promising minimally invasive biomarker for the biological detection of Alzheimer’s disease. This review aimed to evaluate the analytical platforms used for plasma p-tau217 measurement, their diagnostic performance, and the principal challenges associated with its implementation in clinical practice. Methods: A structured narrative review of publications issued between 2019 and 2026 was conducted using PubMed/MEDLINE, Scopus, and Web of Science, with Google Scholar and reference-list screening used as supplementary sources. Studies evaluating plasma p-tau217 assays, analytical validation, diagnostic accuracy, comparison with positron emission tomography or cerebrospinal fluid biomarkers, and clinical implementation were included. Owing to substantial methodological and analytical heterogeneity, findings were synthesised narratively. Results: Plasma p-tau217 showed high diagnostic performance for identifying amyloid and tau pathology and generally outperformed other phosphorylated tau isoforms. Mass-spectrometry-based measurement, particularly percentage p-tau217, demonstrated the highest analytical selectivity and diagnostic accuracy. However, fully automated immunoassays showed greater potential for routine laboratory use because of their higher throughput and reduced technical complexity. Diagnostic performance varied according to the assay, cut-off values, clinical setting, disease prevalence, and patient characteristics. A two-cut-off strategy improved classification while retaining an intermediate group requiring confirmatory testing. Conclusions: Plasma p-tau217 may substantially improve access to biological Alzheimer’s disease diagnostics, but it should not be interpreted as a stand-alone test. Clinical implementation requires assay-specific validation, standardization, external quality control, and integration with clinical assessment and confirmatory diagnostic methods.
- 2 July 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (3(51))
Open AccessPLASMA p-tau217 AS A MINIMALLY INVASIVE BIOMARKER FOR ALZHEIMER’S DISEASE DIAGNOSIS: ANALYTICAL PLATFORMS, DIAGNOSTIC PERFORMANCE, AND CLINICAL IMPLEMENTATION CHALLENGES
Background: Plasma phosphorylated tau at threonine 217 (p-tau217) has emerged as a promising minimally invasive biomarker for the biological detection of Alzheimer’s disease. This review aimed to evaluate the analytical platforms used for plasma p-tau217 measurement, their diagnostic performance, and the principal challenges associated with its implementation in clinical practice. Methods: A structured narrative review of publications issued between 2019 and 2026 was conducted using PubMed/MEDLINE, Scopus, and Web of Science, with Google Scholar and reference-list screening used as supplementary sources. Studies evaluating plasma p-tau217 assays, analytical validation, diagnostic accuracy, comparison with positron emission tomography or cerebrospinal fluid biomarkers, and clinical implementation were included. Owing to substantial methodological and analytical heterogeneity, findings were synthesised narratively. Results: Plasma p-tau217 showed high diagnostic performance for identifying amyloid and tau pathology and generally outperformed other phosphorylated tau isoforms. Mass-spectrometry-based measurement, particularly percentage p-tau217, demonstrated the highest analytical selectivity and diagnostic accuracy. However, fully automated immunoassays showed greater potential for routine laboratory use because of their higher throughput and reduced technical complexity. Diagnostic performance varied according to the assay, cut-off values, clinical setting, disease prevalence, and patient characteristics. A two-cut-off strategy improved classification while retaining an intermediate group requiring confirmatory testing. Conclusions: Plasma p-tau217 may substantially improve access to biological Alzheimer’s disease diagnostics, but it should not be interpreted as a stand-alone test. Clinical implementation requires assay-specific validation, standardization, external quality control, and integration with clinical assessment and confirmatory diagnostic methods.
- Open Access
- 16 April 2026
- Published by Medical Communications Sp. z.o.o. in Pediatria i Medycyna Rodzinna
- Vol. 22 (1) , 58
Scrotal swelling: a urological emergency or a symptom of systemic disease? A case report of nephrotic syndrome
This case report describes a diagnostically challenging presentation of nephrotic syndrome in a two-year-old boy initially suspected to have testicular torsion due to prominent scrotal oedema. The case demonstrates how the characteristic features of nephrotic syndrome – generalised oedema, proteinuria, and hypoalbuminaemia – may be initially obscured by focal symptoms mimicking surgical emergencies. The patient underwent scrotal exploration for suspected appendix testis torsion based on ultrasonography findings; however, postoperative persistence of oedema and development of ascites prompted recognition of the underlying nephrotic syndrome. Prompt initiation of corticosteroid therapy led to rapid resolution of proteinuria and clinical improvement. This report contributes to the existing literature by illustrating how nephrotic syndrome may present atypically, potentially delaying diagnosis when focal symptoms dominate the clinical picture.
- 16 April 2026
- Published by Medical Communications Sp. z.o.o. in Pediatria i Medycyna Rodzinna
- Vol. 22 (1) , 58
Open AccessScrotal swelling: a urological emergency or a symptom of systemic disease? A case report of nephrotic syndrome
This case report describes a diagnostically challenging presentation of nephrotic syndrome in a two-year-old boy initially suspected to have testicular torsion due to prominent scrotal oedema. The case demonstrates how the characteristic features of nephrotic syndrome – generalised oedema, proteinuria, and hypoalbuminaemia – may be initially obscured by focal symptoms mimicking surgical emergencies. The patient underwent scrotal exploration for suspected appendix testis torsion based on ultrasonography findings; however, postoperative persistence of oedema and development of ascites prompted recognition of the underlying nephrotic syndrome. Prompt initiation of corticosteroid therapy led to rapid resolution of proteinuria and clinical improvement. This report contributes to the existing literature by illustrating how nephrotic syndrome may present atypically, potentially delaying diagnosis when focal symptoms dominate the clinical picture.